Faeth Therapeutics, Inc.(FTH)

Biotechnology · Rockville, MD

$26.53-0.57 (-2.10%)

Delayed quote: Oct 6, 2026, 3:35 PM EDT

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T19:36:44.357Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:36:44.357Z.

Quote observation: 2026-10-06T19:35:20.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 683,910,344
Total debt · period ending 2026-06-30: 592,000
Cash · period ending 2026-06-30: 26,903,000
TTM operating income · period ending 2026-06-30: -198,820,000

FMP input reference: 2e4786eb28a8a31d15cdec8f673983fbe0ec0b626c310469f8e20e074e44c13d

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

FTH EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

FTH Competitors' EV/EBIT Ratio

FTH

Faeth Therapeutics, Inc.

Current

Market Cap

$683.91M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

WVE

Wave Life Sciences Ltd.

vs FTH

Market Cap

$689.85M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVR

Anteris Technologies Global Corp.

vs FTH

Market Cap

$688.73M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OLMA

Olema Pharmaceuticals, Inc.

vs FTH

Market Cap

$688.30M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

VSTM

Verastem, Inc.

vs FTH

Market Cap

$684.40M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SLDB

Solid Biosciences Inc.

vs FTH

Market Cap

$676.87M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVBP

ArriVent BioPharma, Inc.

vs FTH

Market Cap

$676.27M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTKB

Cytek Biosciences, Inc.

vs FTH

Market Cap

$704.20M

EV/EBIT Ratio

N/A

TTM Avg

501.20x

3Y Avg

422.57x

5Y Avg

422.57x

COLL

Collegium Pharmaceutical, Inc.

vs FTH

Market Cap

$709.36M

EV/EBIT Ratio

9.07x

TTM Avg

12.78x

3Y Avg

12.26x

5Y Avg

15.40x

AVTX

Avalo Therapeutics, Inc.

vs FTH

Market Cap

$711.21M

EV/EBIT Ratio

N/A

TTM Avg

877.08x

3Y Avg

871.89x

5Y Avg

871.89x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Faeth Therapeutics, Inc. (FTH)	$683.91M	N/A	N/A	N/A	N/A
Wave Life Sciences Ltd. (WVE)vs ›	$689.85M	N/A	N/A	N/A	N/A
Anteris Technologies Global Corp. (AVR)vs ›	$688.73M	N/A	N/A	N/A	N/A
Olema Pharmaceuticals, Inc. (OLMA)vs ›	$688.30M	N/A	N/A	N/A	N/A
Verastem, Inc. (VSTM)vs ›	$684.40M	N/A	N/A	N/A	N/A
Solid Biosciences Inc. (SLDB)vs ›	$676.87M	N/A	N/A	N/A	N/A
ArriVent BioPharma, Inc. (AVBP)vs ›	$676.27M	N/A	N/A	N/A	N/A
Cytek Biosciences, Inc. (CTKB)vs ›	$704.20M	N/A	501.20x	422.57x	422.57x
Collegium Pharmaceutical, Inc. (COLL)vs ›	$709.36M	9.07x	12.78x	12.26x	15.40x
Avalo Therapeutics, Inc. (AVTX)vs ›	$711.21M	N/A	877.08x	871.89x	871.89x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/EBIT Ratio: N/A

FTH EV/EBIT Ratio Metrics

FTH Competitors' EV/EBIT Ratio

EV/EBIT Ratio Formula & Definition

Related Metrics